Edition:
United States

Oramed Pharmaceuticals Inc (ORMP.OQ)

ORMP.OQ on NASDAQ Stock Exchange Capital Market

6.09USD
4:00pm EDT
Change (% chg)

$0.07 (+1.16%)
Prev Close
$6.02
Open
$6.01
Day's High
$6.09
Day's Low
$6.01
Volume
10,259
Avg. Vol
6,547
52-wk High
$10.50
52-wk Low
$5.70

Latest Key Developments (Source: Significant Developments)

Oramed Pharmaceuticals Inc files for mixed shelf of up to $100 mln
Wednesday, 11 Jan 2017 05:34pm EST 

Oramed Pharmaceuticals Inc :Oramed pharmaceuticals inc - files for a mixed shelf of up to $100 million - sec filing.  Full Article

Oramed Pharmaceuticals unit enters into service agreement with XERTECS GmbH
Thursday, 16 Jun 2016 11:57am EDT 

Oramed Pharmaceuticals Inc : On June 13, 2016, Oramed Ltd entered into a service agreement with XERTECS GmbH .As consideration for XERTECS services, subsidiary will pay XERTECS a total amount of up to EUR 2.36 million.  Full Article

Sinopharm Capital-Hefei Signs Letter of Intent with Oramed for $50,000,000 Investment and Licensing Deal in China
Tuesday, 7 Jul 2015 08:00am EDT 

Oramed Pharmaceuticals Inc:Signed a non-binding Letter of Intent (LoI) for an investment and license agreement in China with Sinopharm Capital Management Co. Ltd. and Hefei Life Science & Technology Park Investments and Development Co., Ltd. potentially valued at $50,000,000 plus royalty payments.Oramed will receive $500,000 in exchange for exclusively negotiating with Sinopharm/Hefei for 60 days, while the final terms of the agreement are negotiated and finalized.Transaction which additionally includes 10% royalties on sales, will allow Sinopharm/Hefei to purchase a roughly 10% stake in Oramed Pharmaceuticals and acquire rights for oral insulin in China.Terms are to be broken down as follows: Oramed will sell Sinopharm/Hefei 1,155,367 shares of common stock for approximately $12,000,000.In addition, Oramed's wholly owned subsidiary, Oramed Ltd, will license to Sinopharm/Hefei the exclusive rights to ORMD-0801, oral insulin capsule in China, for a total amount of $38,000,000, of which $18,000,000 will be paid upon the signing of the license agreement.Says remaining $20,000,000 will be paid following the completion, and release of results, of Oramed's current Phase IIb trial in the United States.  Full Article

Guangxi Wuzhou Zhongheng Group subsidiary to invest in Oramed Pharmaceuticals Inc.
Thursday, 2 Jul 2015 08:00pm EDT 

Guangxi Wuzhou Zhongheng Group Co Ltd:Says its Guangxi-based pharmaceutical subsidiary to invest $12 mln into Oramed Pharmaceuticals Inc. (target company), to hold 10 pct stake in the target company.The subsidiary to pay $40 mln to the target company, to obtain the oral administration of insulin in China exclusive production, sales, licensing and related intellectual property rights.  Full Article

Oramed Pharmaceuticals Inc Submits Protocol to FDA for Phase IIb Oral Insulin Study
Tuesday, 30 Jun 2015 08:15am EDT 

Oramed Pharmaceuticals Inc:submits protocol to FDA for its phase IIB oral insulin study.Study has already received IRB approval and patient enrollment is expected to start in the short term.  Full Article

More From Around the Web

BRIEF-Oramed Pharmaceuticals Inc files for mixed shelf of up to $100 mln

* Oramed pharmaceuticals inc - files for a mixed shelf of up to $100 million - sec filing Source text (http://bit.ly/2j8k1FJ) Further company coverage: